KALA stock falls after reverse split as Kala Bio pursues ophthalmology partnerships

KALA stock has dropped sharply after a 1-for-50 reverse split, while Kala Bio pushes ahead with ophthalmology collaborations such as a new genetic testing distribution deal. Investors are weighing the diluted share count against the company’s latest revenue trends.

KALA BIO, Inc. (ISIN US4831191000) stock closed at 0.5322 US dollars on the Nasdaq Capital Market on September 2, 2026, reflecting a steep decline after a recent 1-for-50 reverse split and renewed focus on ophthalmology partnerships.

Reverse split reshapes KALA stock profile

According to market data from Yahoo Finance, KALA BIO shares finished the regular session on September 2, 2026 at 0.5322 US dollars, down 1.82% from the prior close of 0.5421 US dollars.

On the broader performance side, an overview by WallStreetZen shows KALA BIO at a price of 0.53 US dollars, with a 1-day move of minus 20.95% and a six-month performance of minus 97.26%, underscoring how heavily the stock has sold off in recent months.

The same WallStreetZen data lists a 52-week high of 0.51 US dollars and a 52-week low of 0.0003 US dollars, implying that the current price is about 99.95% above the low but still only around 4.31% above the high, a reflection of how reverse split mechanics and price recalibration have distorted the historical range.

Corporate action: 1-for-50 reverse split

A corporate actions tracker from Robinhood notes that KALA BIO, Inc. executed a 1-for-50 reverse split effective September 1, 2026.

Under this action, shareholders now hold 1 KALA share for every 50 shares previously held, and fractional shares resulting from the split are retained, a move typically intended to lift the share price and maintain listing standards on the Nasdaq Capital Market.

For investors, the combination of a reverse split and an immediate price drop of about 20.89% at the September 1, 2026 close, as shown by the KALA chart on Yahoo Finance, highlights lingering skepticism about the company’s fundamentals and future revenue potential.

Latest revenue trend and loss profile

The quarterly overview on Yahoo Finance shows that in the latest reported quarter of fiscal year 2025, KALA BIO generated revenue of roughly 7.56 million US dollars and recorded a quarterly loss of about 10 million US dollars.

Compared with earlier quarters of fiscal year 2024, when losses in some periods were closer to 8 million US dollars, this indicates that the company’s net loss has widened by around 25% in the most recent interim reporting period.

While detailed margin figures are limited in the snapshot, the loss trajectory suggests that KALA BIO still needs to enhance its revenue base and cost structure to move toward break-even in upcoming quarters.

Focus on ophthalmology and genetic testing

KALA BIO positions itself as a specialist in ophthalmology, concentrating on innovative eye care solutions in areas such as dry eye and other ocular surface diseases.

A recent article on The Pharma Vanguard dated September 2, 2026 reports that Kala Bio has signed a letter of intent to distribute ophthalmology genetic tests developed by Virotek, expanding its footprint beyond drug therapies into diagnostics.

This potential collaboration complements the pipeline and could provide incremental revenue opportunities once commercialized, although specific sales or profit projections have not yet been disclosed.

Representative product: Eysuvis eye drops

One of the best-known products associated with Kala Bio’s ophthalmology focus is Eysuvis, a prescription eye drop used for the short-term treatment of dry eye disease and aimed at providing rapid relief for patients.

Dry eye remains a common condition affecting millions of people, and products like Eysuvis sit alongside other eye care solutions and potential future diagnostics such as the Virotek genetic tests mentioned, giving KALA BIO multiple levers to grow its ophthalmology franchise.

KALA stock after September 2, 2026 close

Based on the latest available quote from Yahoo Finance, KALA BIO stock closed at 0.5322 US dollars on September 2, 2026 on the Nasdaq Capital Market, following the 1-for-50 reverse split noted in the Robinhood corporate actions tracker.

For investors, the key question over the coming months will be whether the combination of ophthalmology drug assets, diagnostic partnerships and any forthcoming financial results can stabilize the share price after the dramatic percentage losses seen in the six-month and one-year performance metrics.

KALA BIO stock facts

• Company: KALA BIO, Inc.
• ISIN: US4831191000
• Ticker: KALA
• Trading venue: Nasdaq Capital Market
• Price (as of September 2, 2026): 0.5322 USD
• Market capitalization: 3/9/2026 USD (as of September 2, 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: Nasdaq indices